Nattokinase was first discovered by Dr. Yoko Miyuki. 1980 One day, at 2: 30 in the afternoon, a Japanese cardiologist had to go to see Dr. Yang Hang and add the extract of natto to the simulated artificial thrombus. I wanted to observe the results the next day, and I took a look at it when I got off work at five o'clock. Strange edges appeared, and the thrombus actually dissolved 2 cm. If urokinase takes two days to dissolve a 2 cm thrombus, its thrombolysis speed is 19 times that of urokinase. This is the famous "2: 30 pm experiment" that shocked the history of thrombolysis research in the world. Dr Yang Hang named this thrombus-dissolving substance "nattokinase". From then on, nattokinase became famous and began to be used for thrombolytic therapy of cardiovascular and cerebrovascular diseases. However, it is not difficult to find that the thrombolysis of nattokinase is a simulated thrombolysis in vitro in an ideal laboratory environment, and the real human situation will be much more complicated than this. First of all, nattokinase is a substance in protein that can be decomposed into other substances by gastric acid. Anyone who has attended junior high school should know that nattokinase is easily inactivated in acidic environment. "When the PH value of nattokinase is lower than 5, it will be rapidly denatured and inactivated. The PH value in gastric acid environment is only between 1.2 and 2, and nattokinase can't get through it at all. After being mixed with viscous substances, nattokinase can still keep its activity below 7.5% in acidic environment with PH value of 2-3.
Secondly, nattokinase is a single-stranded polypeptide with a molecular weight of 27728 daltons. 1994 Satoshi Kimura, an honorary professor of the Department of Traditional Chinese Medicine (Ph.D., Peking University), mentioned in his paper that "the absorbable molecular weight of small intestine is below 600, and that of large intestine is below 300", which means that a molecule as big as nattokinase cannot be absorbed by intestine at all. So you can think freely about gains and losses.
Let's talk about lumbrokinase first, which was also invented by Japanese scientist Dr. Meiyuan Heng in the last century. 1986 found that protein of live earthworm can be directly used for thrombolysis, which proved that oral earthworm crude protein extract has the functions of thrombolysis, prevention of thrombosis and reduction of blood viscosity. This was a great achievement at that time and gradually spread to China.
This scheme of extracting active substances from fresh earthworms by freezing method and preserving the activity in the form of freeze-drying is still talked about by people. However, in the late clinical stage, due to some side effects of direct thrombolysis, this lumbrokinase component is listed as a prescription drug in China, so it is not common in the market.
Looking up international patents, we found that Professor Mei Yuanheng registered six patents at that time, including six kinds of protease components, and the application patent number was US 4,568,545. The six protease components are:
The molecular weight of F-O-HM-45 is 24500-2000 daltons.
The molecular weight of F-I- 1-HM-54 is 27500-2000 daltons.
The molecular weight of F-I-2-HM- 15 is 27000 2000 daltons.
The molecular weight of F-II-HM-64 is 27800-2000 Daltons.
The molecular weight of F-III- 1-HM-27 is 32400 2000 daltons.
The molecular weight of F-III-2-HM-89 is 32,800-2,000 daltons.
However, in practical application, we found that lumbrokinase directly acts on human body, which easily leads to side effects such as bleeding and affects human coagulation function. Therefore, it was listed as a prescription drug in China, and in 2009, the Ministry of Health approved lumbrokinase as a new resource food in document 2009 18, and lumbrokinase could not be detected.
Finally, dragon's blood earthworm protein is an extremely trace protein component found in earthworms by Chinese scientists, and its molecular weight is less than 1 0,300 daltons, which is only about 1/20 of the above molecules. This small molecule, called fibrinolytic system activating protein, does not directly dissolve fibrin (the main component of thrombus), but activates the thrombolytic ability of human or animal itself.
Due to the progress of science and technology, it is easy to observe that it is the active component of thrombolysis in earthworm, and it may be the only active component. After the successful patent application, it became the first pharmaceutical molecule in China to have a patent on a compound (until today, we didn't know that artemisinin was patented first by foreign countries because it was eager to publish a paper, which became a permanent regret).
Then why did Professor Meiyuanyuan, one of the first Daniel scientists to study the active components of earthworms, ignore the important fibrinolytic activating factors?
This is because the initial idea of thrombolysis is to dissolve thrombus directly, which is the standard of the experiment. Monomolecular Dragon Ball Albumin is neglected because of its minimal content and only activation. It was not until scientists in China innovatively discovered paper that could activate the human body's ability to dissolve thrombus that it was made public. The human body itself is a very sophisticated machine, which can adjust itself, just like breastfeeding, without causing any adverse reactions. In the case of milk powder accidents, the recovery of one's own ability is the continuation of the theory of broad and precise solution of traditional Chinese medicine. The single molecule of traditional Chinese medicine, which was unknown a few years ago, is gradually blooming with her endless light.